Key facts
- NewLimit’s last known valuation is $1.6B (Oct 2025).
- It has raised $247.3M across 2 recorded rounds; the latest was Later Stage VC ($129.8M) in May 2025.
- Notable investors include Khosla Ventures, Founders Fund, Draper Associates, Abstract Ventures, Valor Equity Partners — 24 tracked in total.
- NewLimit has filed 3 Form Ds with the SEC since 2023, most recently May 2025 ($129.8M sold to 38 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for NewLimit
Funding rounds
2 roundsAbout NewLimit
Developer of precision medicines designed for epigenetic reprogramming to restore youthful function in aging cells. The company applies single-cell genomics, machine learning, and functional assays to study aging, identify epigenetic targets, and develop messenger ribonucleic acid-based therapies that enhance metabolic function in liver cells, enabling researchers and medical professionals to advance treatments for age-related conditions and improve human healthspan.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2021
- Employees
- 43
- Website
- newlimit.com/
- Ownership
- Privately Held (backing)
NewLimit doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NewLimit shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NewLimit in its N-PORT filings yet. We sweep new filings monthly.